EBMT Activity Survey on Hematopoietic Cell Transplantation 2021
The EBMT Activity Survey on Hematopoietic Cell Transplantation (HCT) in 2021 gathered data from 694 teams across 52 countries, totaling 43,109 patients and 47,412 transplants. The survey provides insights into patient numbers, donor types, main indications, and lymphoid neoplasia trends in allogeneic and autologous HCT procedures. Additionally, specific data on allogeneic HCT in Europe is detailed for further analysis.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
E N D
Presentation Transcript
EBMT Activity Survey on HCT 2021 694 Teams 43,109 Patients 47,412 Transplants 52 Countries If you wish to reuse these slides for internal/external presentation, please contact Helen Baldomero: helen.baldomero@usb.ch
EBMT Activity Survey in 2021: Patient and transplant numbers Allogeneic HSCT Autologous HSCT Indication Total 1st allo/1st auto HSCT 18,589 24,520 43,109 Additional HSCT 1,217 3,086 4,303 TOTAL all transplants 19,806 27,606 47,412 Teams: 694 Countries reporting: 52
EBMT Activity Survey in 2021: Donor type and stem cell source: all transplants Donor type BM PBSC Cord Total 4256 32 5,510 HLA-id sibling 1222 3071 n.a. 3,785 Haplo-identical 714 178 2 236 Other family 56 n.a n.a. 22 Syngeneic n.a. 8910 291 10,253 Unrelated 1052 16,415 325 19,806 Allogeneic 3044 27,545 0 27,606 Autologous 61
EBMT Activity Survey in 2021: Main indications Allogeneic 1st HSCT Autologous 1st HSCT Indication Total Myeloid (AML, CML, MDS/MPN) 10,745 227 10,972 Lymphoid (ALL, CLL, HL, NHL) 4858 8754 13,612 Plasma cell disorder 269 13,375 13,644 Solid tumor 52 1635 1687 Non-malignant disorders (all) 2501 503 3004 bone marrow failure 986 2 988 auto immune disease 20 468 488 Other 164 26 190 Total Patients 18,589 24,520 43,109
EBMT Activity Survey in 2021 Lymphoid neoplasia Allogeneic 1st Tx. Autologous 1st Tx. Indication Total 13,170 PCD - Myeloma 233 12,937 474 PCD - Other 36 438 2,705 HD 410 2,295 7,463 NHL 1115 6,348
Allogeneic HCT in Europe 2021: 1st HCT Passweg, Baldomero et al. Bone Marrow Transplant. 2023 Mar 6:1-12
Autologous HCT in Europe 2021: 1st HCT Passweg, Baldomero et al. Bone Marrow Transplant. 2023 Mar 6:1-12
HCT activity in Europe 1990-2021: allogeneic vs autologous HCT Passweg, Baldomero et al. Bone Marrow Transplant. 2023 Mar 6:1-12
HCT activity in Europe 1990-2021: donor origin: 1st HCT Passweg, Baldomero et al. Bone Marrow Transplant. 2023 Mar 6:1-12
HCT activity in Europe 1990-2021: cord blood HCT: all transplants
HCT activity in Europe 1990-2021: main indication: allogeneic HCT
HCT activity in Europe 1990-2021: myeloid disorders: allogeneic HCT
HCT activity in Europe 1990-2021: main indication: autologous HCT
EBMT Activity Survey on Cellular therapies For internal use only. For any other use, please contact Helen Baldomero: helen.baldomero@usb.ch
Cellular therapies in Europe 2021 selected/expa nded T cells or CIK Genetically modified T cells Genetically modified CD34+ cells Regulatory T cells (TREGS) Expanded CD34+ cells Number of patients DLI CART MSC NK cells Dendritic cells Other Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto GvHD 280 1 7 1 1 1 1 1 6 Graft enhancement 25 8 17 2 7 2 152 37 Autoimmune dis. 4 17 8 1 Genetic disease 29 Infection 13 9 135 15 5 7 3 5 3 Malignancy - ALL 42 337 5 9 1 10 1 5 2 4 Malignancy - HL/NHL 4 1847 1 5 1 1 1 5 Malignancy - Other 12 278 13 3 21 13 2 15 17 3 16 17 DLI for graft enhancement/failure DLI for residual disease 848 540 DLI for relapse 1377 DLI per protocol 480 Total 3245 58 2466 340 9 31 5 179 45 15 1 10 19 2 22 9 1 7 29 178 68 Passweg, Baldomero et al. Bone Marrow Transplant. 2023 Mar 6:1-12
